NewcelX Enters Strategic Collaboration With Eledon Pharma

March 09, 2026 — 09:50 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - NewcelX Ltd. (NCEL) announced a collaborative research agreement with Eledon Pharmaceuticals (ELDN), a clinical-stage immunology company with a focus on transplant medicine. It is designed to advance combination strategies integrating NewcelX's lead program, NCEL-101, with Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart or AT-1501, with the goal of supporting durable, immune-protected islet replacement and advancing a potential functional cure for Type 1 Diabetes.

The company said the collaboration is anticipated to accelerate timelines, establish a well-defined regulatory pathway, and enhance development visibility, supporting NewcelX's strategy to advance its clinical programs efficiently toward pivotal milestones.

NewcelX shares are currently trading at $2.9450, up 6.32%.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

NewcelX Enters Strategic Collaboration With Eledon Pharma

Tags

Latest Articles